1 line
12 KiB
Plaintext
1 line
12 KiB
Plaintext
{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T05:59:46Z","timestamp":1705298386592},"reference-count":19,"publisher":"Elsevier BV","issue":"10382","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/s0140-6736(23)00350-1","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T23:29:33Z","timestamp":1677626973000},"page":"1079-1090","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial"],"prefix":"10.1016","volume":"401","author":[{"given":"Timothy J","family":"Craig","sequence":"first","affiliation":[]},{"given":"Avner","family":"Reshef","sequence":"additional","affiliation":[]},{"given":"H Henry","family":"Li","sequence":"additional","affiliation":[]},{"given":"Joshua S","family":"Jacobs","sequence":"additional","affiliation":[]},{"given":"Jonathan A","family":"Bernstein","sequence":"additional","affiliation":[]},{"given":"Henriette","family":"Farkas","sequence":"additional","affiliation":[]},{"given":"William H","family":"Yang","sequence":"additional","affiliation":[]},{"given":"Erik S G","family":"Stroes","sequence":"additional","affiliation":[]},{"given":"Isao","family":"Ohsawa","sequence":"additional","affiliation":[]},{"given":"Raffi","family":"Tachdjian","sequence":"additional","affiliation":[]},{"given":"Michael E","family":"Manning","sequence":"additional","affiliation":[]},{"given":"William R","family":"Lumry","sequence":"additional","affiliation":[]},{"given":"Inmaculada Martinez","family":"Saguer","sequence":"additional","affiliation":[]},{"given":"Emel","family":"Ayg\u00f6ren-P\u00fcrs\u00fcn","sequence":"additional","affiliation":[]},{"given":"Bruce","family":"Ritchie","sequence":"additional","affiliation":[]},{"given":"Gordon L","family":"Sussman","sequence":"additional","affiliation":[]},{"given":"John","family":"Anderson","sequence":"additional","affiliation":[]},{"given":"Kimito","family":"Kawahata","sequence":"additional","affiliation":[]},{"given":"Yusuke","family":"Suzuki","sequence":"additional","affiliation":[]},{"given":"Petra","family":"Staubach","sequence":"additional","affiliation":[]},{"given":"Regina","family":"Treudler","sequence":"additional","affiliation":[]},{"given":"Henrike","family":"Feuersenger","sequence":"additional","affiliation":[]},{"given":"Fiona","family":"Glassman","sequence":"additional","affiliation":[]},{"given":"Iris","family":"Jacobs","sequence":"additional","affiliation":[]},{"given":"Markus","family":"Magerl","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(23)00350-1_bib1","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/all.15214","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema\u2013the 2021 revision and update","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/S0140-6736(23)00350-1_bib2","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","article-title":"US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema","volume":"9","author":"Busse","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/S0140-6736(23)00350-1_bib3","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00005792-199207000-00003","article-title":"Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients","volume":"71","author":"Agostoni","year":"1992","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/S0140-6736(23)00350-1_bib4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.anai.2013.08.019","article-title":"The burden of illness in patients with hereditary angioedema","volume":"111","author":"Banerji","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/S0140-6736(23)00350-1_bib5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1750-1172-9-99","article-title":"Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe","volume":"9","author":"Ayg\u00f6ren-P\u00fcrs\u00fcn","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/S0140-6736(23)00350-1_bib6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13223-021-00537-2","article-title":"Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report","volume":"17","author":"Bork","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/S0140-6736(23)00350-1_bib7","first-page":"3006","article-title":"The elusive physiologic role of Factor XII","volume":"118","author":"Schmaier","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/S0140-6736(23)00350-1_bib8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.transci.2003.08.012","article-title":"The pathogenesis of hereditary angioedema","volume":"29","author":"Davis","year":"2003","journal-title":"Transfus Apheresis Sci"},{"key":"10.1016\/S0140-6736(23)00350-1_bib9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jaci.2016.02.041","article-title":"Angioedema attacks in patients with hereditary angioedema: local manifestations of a systemic activation process","volume":"138","author":"Hofman","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/S0140-6736(23)00350-1_bib10","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1016\/j.bbamcr.2017.07.009","article-title":"The plasma contact system, a protease cascade at the nexus of inflammation, coagulation and immunity","volume":"1864","author":"Weidmann","year":"2017","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"10.1016\/S0140-6736(23)00350-1_bib11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12016-021-08832-x","article-title":"Current and prospective targets of pharmacologic treatment of hereditary angioedema types 1 and 2","volume":"61","author":"Fijen","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/S0140-6736(23)00350-1_bib12","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1613627","article-title":"Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor","volume":"376","author":"Longhurst","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(23)00350-1_bib13","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1001\/jama.2018.16773","article-title":"Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial","volume":"320","author":"Banerji","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/S0140-6736(23)00350-1_bib14","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.jaci.2018.06.014","article-title":"Antibody-mediated inhibition of FXIIa blocks downstream bradykinin generation","volume":"142","author":"Cao","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/S0140-6736(23)00350-1_bib15","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(21)02225-X","article-title":"Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"399","author":"Craig","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(23)00350-1_bib16","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.jaip.2019.01.054","article-title":"Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks","volume":"7","author":"Craig","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/S0140-6736(23)00350-1_bib17","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/all.12900","article-title":"The Angioedema Quality of Life Questionnaire (AE-QoL)\u2014assessment of sensitivity to change and minimal clinically important difference","volume":"71","author":"Weller","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/S0140-6736(23)00350-1_bib18","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1182\/blood-2012-07-292094","article-title":"In vivo roles of factor XII","volume":"120","author":"Renn\u00e9","year":"2012","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(23)00350-1_bib20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jaci.2020.10.015","article-title":"Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"148","author":"Zuraw","year":"2021","journal-title":"J Allergy Clin Immunol"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673623003501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673623003501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T16:17:42Z","timestamp":1682007462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673623003501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":19,"journal-issue":{"issue":"10382","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0140673623003501"],"URL":"http:\/\/dx.doi.org\/10.1016\/s0140-6736(23)00350-1","relation":{},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":["General Medicine"],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(23)00350-1","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(23)00092-2","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}} |